Skip to main content
. 2021 Jul 13;10(17):5809–5822. doi: 10.1002/cam4.4127

FIGURE 2.

FIGURE 2

(A) Time‐on‐treatment (TOT) for first‐line treatment with afatinib in all patients (n = 324) with advanced NSCLC harboring EGFR mutations. (B) TOT with afatinib, when osimertinib (group A, n = 126) and other medications (group B, n = 198) are used as second‐line treatment